Targeting calcium and the mitochondria in prevention of pathology in the heart

Current Drug Targets

Volumn 12, Issue 5, 2011, Pages 748-760

  Viola, Helena M ^a,b   Hool, Livia C ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Calcium; Cardiac hypertrophy; Mitochondria; Reactive oxygen species

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CALCIUM; MANGANESE SUPEROXIDE DISMUTASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRICARBOXYLIC ACID;

ARTICLE; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CELL MEMBRANE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MITOCHONDRION; MUSCLE CELL; OXIDATIVE STRESS; RESPIRATORY CHAIN;

ANIMALS; CALCIUM; CALCIUM CHANNELS; CARDIOMEGALY; HEART; HUMANS; MITOCHONDRIA, HEART; MOLECULAR TARGETED THERAPY; MYOCARDIUM; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 79953300107     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945011795378603     Document Type: Article

References (185)

1. Bers DM. Cardiac excitation-contraction coupling. Nature 2002; 415: 198-205.
2. Campbell DL, Stamler JS, Strauss HC. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J Gen Physiol 1996; 108: 277-93.
3. Lipton SA, Choi YB, Pan ZH, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993; 364: 626-32.
4. Gilbert HF. Molecular and cellular aspects of thiol-disulfide exchange. Adv Enzymol Relat Areas Mol Biol 1990; 63: 69-172.
5. Stone JR, Yang S. Hydrogen peroxide: a signaling messenger. Antioxid Redox Signal 2006; 8: 243-70.
6. Halliwell B. The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 1993; 23 (Suppl 1): 118-26.
7. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res 2006; 71: 208-15.
8. Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002; 34: 379-88.
9. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005; 115: 500-8.
10. Sabri A, Hughie HH, Lucchesi PA. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid Redox Signal 2003; 5: 731-40.
11. Bolli R. Causative role of oxyradicals in myocardial stunning: a proven hypothesis. A brief review of the evidence demonstrating a major role of reactive oxygen species in several forms of postischemic dysfunction. Basic Res Cardiol 1998; 93: 156-62.
12. Grieve DJ, Byrne JA, Cave AC, Shah AM. Role of oxidative stress in cardiac remodelling after myocardial infarction. Heart Lung Circ 2004; 13: 132-8.
13. Turrens JF. Superoxide production by the mitochondrial respiratory chain. Biosci Rep 1997; 17: 3-8.
14. 2+ signalling systems and cardiac hypertrophy. Biochem Soc Trans 2006; 34: 228-31.
15. Berridge MJ. Calcium microdomains: organization and function. Cell Calcium 2006; 40: 405-12.
16. Marks AR. Cellular functions of immunophilins. Physiol Rev 1996; 76: 631-49.
17. Jayaraman T, Brillantes AM, Timerman AP, et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem 1992; 267: 9474-7.
18. Timerman AP, Onoue H, Xin HB, et al. Selective binding of FKBP12.6 by the cardiac ryanodine receptor. J Biol Chem 1996; 271: 20385-91.
19. Xin HB, Senbonmatsu T, Cheng DS, et al. Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature 2002; 416: 334-8.
20. Kirchhefer U, Neumann J, Baba HA, et al. Cardiac hypertrophy and impaired relaxation in transgenic mice overexpressing triadin 1. J Biol Chem 2001; 276: 4142-9.
21. Viola HM, Hool LC. The Role of Calcium and the L-Type Calcium Channel in Pathological Remodeling of the Heart. Vasc Dis Prevent 2008; 5: 104-15.
22. Cooper G, 4th. Cardiocyte adaptation to chronically altered load. Annu Rev Physiol 1987; 49: 501-18.
23. Mondry A, Swynghedauw B. Biological adaptation of the myocardium to chronic mechanical overload. Molecular determinants of the autonomic nervous system. Eur Heart J 1995; 16 (Suppl I): 64-73.
24. Frey N, Olson EN. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79.
25. Wilkins BJ, Molkentin JD. Calcineurin and cardiac hypertrophy: where have we been? Where are we going? J Physiol 2002; 541: 1-8.
26. Carafoli E, Santella L, Branca D, Brini M. Generation, control, and processing of cellular calcium signals. Crit Rev Biochem Mol Biol 2001; 36: 107-260.
27. Bodi I, Mikala G, Koch SE, Akhter SA, Schwartz A. The L-type calcium channel in the heart: the beat goes on. J Clin Invest 2005; 115: 3306-17.
28. Bers DM. Calcium cycling and signaling in cardiac myocytes. Annu Rev Physiol 2008; 70: 23-49.
29. Hool LC, Corry B. Redox control of calcium channels: from mechanisms to therapeutic opportunities. Antioxid Redox Signal 2007; 9: 409-35.
30. Hool LC. What cardiologists should know about calcium ion channels and their regulation by reactive oxygen species. Heart Lung Circ 2007; 16: 361-72.
31. Bezprozvanny I, Watras J, Ehrlich BE. Bell-shaped calcium-response curves of Ins(1,4,5)P3- and calcium-gated channels from endoplasmic reticulum of cerebellum. Nature 1991; 351: 751-4.
32. 2+ channels have different effects on myocyte contractility and induce unique cardiac phenotypes. Circ Res 2008; 103: 1109-19.
33. Nakayama H, Wilkin BJ, Bodi I, Molkentin JD. Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart. FASEB J 2006; 20: 1660-70.
34. Guinamard R, Demion M, Chatelier A, Bois P. Calcium-activated nonselective cation channels in mammalian cardiomyocytes. Trends Cardiovasc Med 2006; 16: 245-50.
35. Balaban RS. Cardiac energy metabolism homeostasis: role of cytosolic calcium. J Mol Cell Cardiol 2002; 34: 1259-71.
36. Brookes PS, Yoon Y, Robotham JL, Anders MW, Sheu SS. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol 2004; 287: C817-33.
37. 2+ uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes. Circ Res 2006; 99: 172-82.
38. Kirichok Y, Krapivinsky G, Clapham DE. The mitochondrial calcium uniporter is a highly selective ion channel. Nature 2004; 427: 360-4.
39. 2+ exchange. Proc Natl Acad Sci USA 2010; 107: 436-41.
40. Sheeran FL, Pepe S. Energy deficiency in the failing heart: linking increased reactive oxygen species and disruption of oxidative phosphorylation rate. Biochim Biophys Acta 2006; 1757: 543-52.
41. Cortassa S, Aon MA, Marban E, Winslow RL, O'Rourke B. An integrated model of cardiac mitochondrial energy metabolism and calcium dynamics. Biophys J 2003; 84: 2734-55.
42. + ratios. Biochem J 1988; 252: 181-9.
43. 2+. Biochem J 1984; 218: 235-47.
44. 2+, adenine nucleotides and pH on the kinetic properties of mitochondrial NAD(+)-isocitrate dehydrogenase and oxoglutarate dehydrogenase from the yeast Saccharomyces cerevisiae and rat heart. Biochem J 1994; 303 (Pt 2): 461-5.
45. McCormack JG, Halestrap AP, Denton RM. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev 1990; 70: 391-425.
46. Hansford RG, Zorov D. Role of mitochondrial calcium transport in the control of substrate oxidation. Mol Cell Biochem 1998; 184: 359-69.
47. 2+ channels and mitochondria. Clin Exp Pharmacol Physiol 2010; 37: 229-35.
48. Aon MA, Cortassa S, Marban E, O'Rourke B. Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes. J Biol Chem 2003; 278: 44735-44.
49. Ricci JE, Waterhouse N, Green DR. Mitochondrial functions during cell death, a complex (I-V) dilemma. Cell Death Differ 2003; 10: 488-92.
50. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol 2003; 552: 335-44.
51. Muller FL, Roberts AG, Bowman MK, Kramer DM. Architecture of the Qo site of the cytochrome bc1 complex probed by superoxide production. Biochemistry 2003; 42: 6493-9.
52. St-Pierre J, Buckingham JA, Roebuck SJ, Brand MD. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J Biol Chem 2002; 277: 44784-90.
53. Grigorieff N. Structure of the respiratory NADH: ubiquinone oxidoreductase (complex I). Curr Opin Struct Biol 1999; 9: 476-83.
54. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production of reactive oxygen species by mitochondria: central role of complex III. J Biol Chem 2003; 278: 36027-31.
55. Gille L, Nohl H. The ubiquinol/bc1 redox couple regulates mitochondrial oxygen radical formation. Arch Biochem Biophys 2001; 388: 34-8.
56. Han D, Antunes F, Canali R, Rettori D, Cadenas E. Voltage-dependent anion channels control the release of the superoxide anion from mitochondria to cytosol. J Biol Chem 2003; 278: 5557-63.
57. Boveris A, Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem J 1973; 134: 707-16.
58. Gunter TE, Sheu SS. Characteristics and possible functions of mitochondrial Ca(2+) transport mechanisms. Biochim Biophys Acta 2009; 1787: 1291-308.
59. Graham D, Huynh NN, Hamilton CA, et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 2009; 54: 322-8.
60. Andreyev AY, Kushnareva YE, Starkov AA. Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc) 2005; 70: 200-14.
61. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009; 417: 1-13.
62. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000; 279: L1005-28.
63. 2+ channel function in the absence of apoptosis in ventricular myocytes. Circ Res 2007; 100: 1036-44.
64. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
65. + channels prevent oxidative stress, permeability transition and cell death. J Bioenerg Biomembr 2005; 37: 75-82.
66. Przygodzki T, Sokal A, Bryszewska M. Calcium ionophore A23187 action on cardiac myocytes is accompanied by enhanced production of reactive oxygen species. Biochim Biophys Acta 2005; 1740: 481-8.
67. 2+ channel in ventricular myocytes. J Mol Cell Cardiol 2009; 46: 1016-26.
68. van Empel VP, De Windt LJ. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res 2004; 63: 487-99.
69. Wilkins BJ, Molkentin JD. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem Biophys Res Commun 2004; 322: 1178-91.
70. nd, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005; 115: 527-37.
71. Hool LC. Reactive oxygen species in cardiac signalling: from mitochondria to plasma membrane ion channels. Clin Exp Pharmacol Physiol 2006; 33: 146-51.
72. Ruwhof C, van der Laarse A. Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc Res 2000; 47: 23-37.
73. Newton AC. Protein kinase C: structure, function, and regulation. J Biol Chem 1995; 270: 28495-8.
74. Wang J, Liu X, Arneja AS, Dhalla NS. Alterations in protein kinase A and protein kinase C levels in heart failure due to genetic cardiomyopathy. Can J Cardiol 1999; 15: 683-90.
75. McKinsey TA. Depression of pathological cardiac genes by members of the CaM kinase superfamily. Cardiovasc Res 2007; 73: 667-77.
76. Malhotra A, Kang BP, Opawumi D, Belizaire W, Meggs LG. Molecular biology of protein kinase C signaling in cardiac myocytes. Mol Cell Biochem 2001; 225: 97-107.
77. Poole AW, Pula G, Hers I, Crosby D, Jones ML. PKC-interacting proteins: from function to pharmacology. Trends Pharmacol Sci 2004; 25: 528-35.
78. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 2002; 40: 477-84.
79. Byrne JA, Grieve DJ, Bendall JK, et al. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 2003; 93: 802-5.
80. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002; 105: 293-6.
81. Doerries C, Grote K, Hilfiker-Kleiner D, et al. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res 2007; 100: 894-903.
82. Bergamini C, Cicoira M, Rossi A, Vassanelli C. Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 2009; 11: 444-52.
83. Engberding N, Spiekermann S, Schaefer A, et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 2004; 110: 2175-9.
84. Umar S, van der Laarse A. Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem 2010; 333: 191-201.
85. Pritchard KA, Jr., Ackerman AW, Gross ER, et al. Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric-oxide synthase. J Biol Chem 2001; 276: 17621-4.
86. Takimoto E, Champion HC, Li M, et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005; 115: 1221-31.
87. 2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats. Hypertension 2003; 41: 963-7.
88. Wenzel S, Rohde C, Wingerning S, Roth J, Kojda G, Schluter KD. Lack of endothelial nitric oxide synthase-derived nitric oxide formation favors hypertrophy in adult ventricular cardiomyocytes. Hypertension 2007; 49: 193-200.
89. Ichinose F, Bloch KD, Wu JC, et al. Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency. Am J Physiol Heart Circ Physiol 2004; 286: H1070-5.
90. Ozaki M, Kawashima S, Yamashita T, et al. Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion. Circ J 2002; 66: 851-6.
91. Janssens S, Pokreisz P, Schoonjans L, et al. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 2004; 94: 1256-62.
92. Buys ES, Raher MJ, Blake SL, et al. Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload. Am J Physiol Heart Circ Physiol 2007; 293: H620-7.
93. Ruetten H, Dimmeler S, Gehring D, Ihling C, Zeiher AM. Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. Cardiovasc Res 2005; 66: 444-53.
94. Kowaltowski AJ, Vercesi AE. Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med 1999; 26: 463-71.
95. 2+ channel function during acute hypoxia. Cardiovasc Res 2005; 67: 624-35.
96. Ide T, Tsutsui H, Hayashidani S, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 2001; 88: 529-35.
97. Li Y, Huang TT, Carlson EJ, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995; 11: 376-81.
98. Loch T, Vakhrusheva O, Piotrowska I, et al. Different extent of cardiac malfunction and resistance to oxidative stress in heterozygous and homozygous manganese-dependent superoxide dismutase-mutant mice. Cardiovasc Res 2009; 82: 448-57.
99. Shiomi T, Tsutsui H, Matsusaka H, et al. Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 2004; 109: 544-9.
100. Matsushima S, Ide T, Yamato M, et al. Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 2006; 113: 1779-86.
101. Yamamoto M, Yang G, Hong C, et al. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 2003; 112: 1395-406.
102. Widder JD, Fraccarollo D, Galuppo P, et al. Attenuation of angiotensin II-induced vascular dysfunction and hypertension by overexpression of Thioredoxin 2. Hypertension 2009; 54: 338-44.
103. Seznec H, Simon D, Monassier L, et al. Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Genet 2004; 13: 1017-24.
104. van Empel VP, Bertrand AT, van der Nagel R, et al. Downregulation of apoptosis-inducing factor in harlequin mutant mice sensitizes the myocardium to oxidative stress-related cell death and pressure overload-induced decompensation. Circ Res 2005; 96: e92-e101.
105. van Empel VP, Bertrand AT, van Oort RJ, et al. EUK-8, a superoxide dismutase and catalase mimetic, reduces cardiac oxidative stress and ameliorates pressure overload-induced heart failure in the harlequin mouse mutant. J Am Coll Cardiol 2006; 48: 824-32.
106. Kalenikova EI, Gorodetskaya EA, Kolokolchikova EG, Shashurin DA, Medvedev OS. Chronic administration of coenzyme Q10 limits postinfarct myocardial remodeling in rats. Biochemistry (Mosc) 2007; 72: 332-8.
107. Harker-Murray AK, Tajik AJ, Ishikura F, Meyer D, Burnett JC, Redfield MM. The role of coenzyme Q10 in the pathophysiology and therapy of experimental congestive heart failure in the dog. J Card Fail 2000; 6: 233-42.
108. Hool LC. Hypoxia increases the sensitivity of the L-type Ca(2+) current to beta-adrenergic receptor stimulation via a C2 region-containing protein kinase C isoform. Circ Res 2000; 87: 1164-71.
109. 2+ channel to beta-adrenergic receptor stimulation in cardiac myocytes. Circ Res 2002; 91: 601-9.
110. 2+ channel alpha1C subunits but does not mediate their sensitivity to acute hypoxia. Biochem Biophys Res Commun 2004; 318: 135-41.
111. Hool LC. Hypoxia alters the sensitivity of the L-type Ca(2+) channel to alpha-adrenergic receptor stimulation in the presence of beta-adrenergic receptor stimulation. Circ Res 2001; 88: 1036-43.
112. Sims C, Harvey RD. Redox modulation of basal and beta-adrenergically stimulated cardiac L-type Ca(2+) channel activity by phenylarsine oxide. Br J Pharmacol 2004; 142: 797-807.
113. 2+ currents through L-type channels in cultured rat dentate granule cells. Neurosci Lett 2004; 356: 25-8.
114. Viola HM, Macdonald WA, Tang H, Hool LC. The L-type Ca(2+) Channel as a Therapeutic Target in Heart Disease. Curr Med Chem 2009; 16: 3341-58.
115. 2+ channel alpha1C subunits by redox agents and hypoxia. J Physiol 1999; 514 (Pt 3): 629-37.
116. Dulhunty A, Haarmann C, Green D, Hart J. How many cysteine residues regulate ryanodine receptor channel activity? Antioxid Redox Signal 2000; 2: 27-34.
117. Sun J, Xu L, Eu JP, Stamler JS, Meissner G. Classes of thiols that influence the activity of the skeletal muscle calcium release channel. J Biol Chem 2001; 276: 15625-30.
118. 2+ release from sarcoplasmic reticulum. Mol Cell Biochem 1988; 82: 81-4.
119. Trimm JL, Salama G, Abramson JJ. Sulfhydryl oxidation induces rapid calcium release from sarcoplasmic reticulum vesicles. J Biol Chem 1986; 261: 16092-8.
120. 2+ release from sarcoplasmic reticulum via an oxidation reaction. J Biol Chem 1989; 264: 21725-36.
121. Anzai K, Ogawa K, Ozawa T, Yamamoto H. Oxidative modification of ion channel activity of ryanodine receptor. Antioxid Redox Signal 2000; 2: 35-40.
122. 2+ regulatory protein and potential therapeutic drug target. Curr Drug Targets 2011; 12(5): 709-23.
123. Hidalgo C, Bull R, Marengo JJ, Perez CF, Donoso P. SH oxidation stimulates calcium release channels (ryanodine receptors) from excitable cells. Biol Res 2000; 33: 113-24.
124. 2+ release mechanism. J Biol Chem 1997; 272: 7069-77.
125. 2+ release channel. J Biol Chem 1997; 272: 3739-48.
126. Eager KR, Dulhunty AF. Cardiac ryanodine receptor activity is altered by oxidizing reagents in either the luminal or cytoplasmic solution. J Membr Biol 1999; 167: 205-14.
127. 2+ spikes in HeLa cells by sensitizing the inositol 1,4,5-trisphosphate receptor. J Biol Chem 1992; 267: 25113-9.
128. Missiaen L, Taylor CW, Berridge MJ. Spontaneous calcium release from inositol trisphosphate-sensitive calcium stores. Nature 1991; 352: 241-4.
129. Lopez-Colome AM, Lee I. Pharmacological characterization of inositol-1,4,5,-trisphosphate binding to membranes from retina and retinal cultures. J Neurosci Res 1996; 44: 149-56.
130. Renard-Rooney DC, Joseph SK, Seitz MB, Thomas AP. Effect of oxidized glutathione and temperature on inositol 1,4,5-trisphosphate binding in permeabilized hepatocytes. Biochem J 1995; 310 (Pt 1): 185-92.
131. 2+ release from vascular smooth muscle sarcoplasmic reticulum. Am J Physiol 1992; 262: H114-6.
132. 2+ stores to inositol 1,4,5-trisphosphate in human endothelial cells. J Biol Chem 2000; 275: 15749-57.
133. Adachi T, Weisbrod RM, Pimentel DR, et al. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med 2004; 10: 1200-7.
134. 2+ mobilisation in human platelets through sulphydryl oxidation dependent and independent mechanisms. Biochem Pharmacol 2004; 67: 491-502.
135. 2+ pumps of coronary artery. Am J Physiol 1988; 255: C297-303.
136. Suzuki YJ, Edmondson JD, Ford GD. Inactivation of rabbit muscle creatine kinase by hydrogen peroxide. Free Radic Res Commun 1992; 16: 131-6.
137. 2+ depletion in cardiac myocytes. Free Radic Biol Med 2010; 48: 1182-7.
138. 2+-ATPase. Biochemistry 2005; 44: 11074-81.
139. Anbanandam A, Bieber Urbauer RJ, Bartlett RK, Smallwood HS, Squier TC, Urbauer JL. Mediating molecular recognition by methionine oxidation: conformational switching by oxidation of methionine in the carboxyl-terminal domain of calmodulin. Biochemistry 2005; 44: 9486-96.
140. Chen B, Mayer MU, Squier TC. Structural uncoupling between opposing domains of oxidized calmodulin underlies the enhanced binding affinity and inhibition of the plasma membrane Ca-ATPase. Biochemistry 2005; 44: 4737-47.
141. 2+-ATPase by hydrogen peroxide and protection by calmodulin. Biochemistry 2003; 42: 12001-10.
142. 2+ exchanger. J Biol Chem 1999; 274: 910-7.
143. Lehotsky J, Kaplan P, Racay P, Matejovicova M, Drgova A, Mezesova V. Membrane ion transport systems during oxidative stress in rodent brain: protective effect of stobadine and other antioxidants. Life Sci 1999; 65: 1951-8.
144. 2+ exchanger, NCKX2. J Biol Chem 2002; 277: 48923-30.
145. 2+ exchanger in the pathophysiology of cardiac arrhythmia, ischemia and heart failure. Curr Drug Targets 2011; 12(5): 737-47.
146. Kwon SH, Pimentel DR, Remondino A, Sawyer DB, Colucci WS. H(2)O(2) regulates cardiac myocyte phenotype via concentration-dependent activation of distinct kinase pathways. J Mol Cell Cardiol 2003; 35: 615-21.
147. Chen QM, Tu VC, Wu Y, Bahl JJ. Hydrogen peroxide dose dependent induction of cell death or hypertrophy in cardiomyocytes. Arch Biochem Biophys 2000; 373: 242-8.
148. Tu VC, Bahl JJ, Chen QM. Signals of oxidant-induced cardiomyocyte hypertrophy: key activation of p70 S6 kinase-1 and phosphoinositide 3-kinase. J Pharmacol Exp Ther 2002; 300: 1101-10.
149. Seenarain V, Viola HM, Ravenscroft G, et al. Evidence of altered guinea pig ventricular cardiomyocyte protein expression and growth in response to a 5 min in vitro exposure to H(2)O(2). J Proteome Res 2010; 9: 1985-94.
150. 2+ oscillation. EMBO J 2003; 22: 3825-32.
151. 2+ response amplitude and duration. Nature 1997; 386: 855-8.
152. Viola HM, Hool LC. Q(o) site of mitochondrial complex III is the source of increased superoxide after transient exposure to hydrogen peroxide. J Mol Cell Cardiol 2010; 49: 875-85.
153. Ago T, Sadoshima J. Thioredoxin1 as a negative regulator of cardiac hypertrophy. Antioxid Redox Signal 2007; 9: 679-87.
154. Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH. 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol Med 2005; 11: 571-8.
155. Nordberg J, Arner ES. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic Biol Med 2001; 31: 1287-312.
156. Chae HZ, Kim HJ, Kang SW, Rhee SG. Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. Diabetes Res Clin Pract 1999; 45: 101-12.
157. Chae HZ, Kang SW, Rhee SG. Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin. Methods Enzymol 1999; 300: 219-26.
158. Spyrou G, Enmark E, Miranda-Vizuete A, Gustafsson J. Cloning and expression of a novel mammalian thioredoxin. J Biol Chem 1997; 272: 2936-41.
159. Miranda-Vizuete A, Ljung J, Damdimopoulos AE, et al. Characterization of Sptrx, a novel member of the thioredoxin family specifically expressed in human spermatozoa. J Biol Chem 2001; 276: 31567-74.
160. Watson WH, Yang X, Choi YE, Jones DP, Kehrer JP. Thioredoxin and its role in toxicology. Toxicol Sci 2004; 78: 3-14.
161. Schulz JB, Dehmer T, Schols L, et al. Oxidative stress in patients with Friedreich ataxia. Neurology 2000; 55: 1719-21.
162. Emond M, Lepage G, Vanasse M, Pandolfo M. Increased levels of plasma malondialdehyde in Friedreich ataxia. Neurology 2000; 55: 1752-3.
163. Chantrel-Groussard K, Geromel V, Puccio H, et al. Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum Mol Genet 2001; 10: 2061-7.
164. Meier T, Buyse G. Idebenone: an emerging therapy for Friedreich ataxia. J Neurol 2009; 256 (Suppl 1): 25-30.
165. McCarty MF. Practical prevention of cardiac remodeling and atrial fibrillation with full-spectrum antioxidant therapy and ancillary strategies. Med Hypotheses 2010; 75(2): 141-7.
166. Sucharov CC, Mariner PD, Nunley KR, Long C, Leinwand L, Bristow MR. A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction. Am J Physiol Heart Circ Physiol 2006; 291: H1299-308.
167. + current changes and action potential duration. J Am Coll Cardiol 2003; 41: 1611-22.
168. 2+-dependent calcineurin activation in mechanical stretch-induced hypertrophy. Cardiology 2007; 107: 281-90.
169. 2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 2007; 117: 2431-44.
170. Haase H, Kresse A, Hohaus A, et al. Expression of calcium channel subunits in the normal and diseased human myocardium. J Mol Med 1996; 74: 99-104.
171. Splawski I, Timothy KW, Decher N, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci USA 2005; 102: 8089-96; discussion 6-8.
172. Yamaguchi N, Takahashi N, Xu L, Smithies O, Meissner G. Early cardiac hypertrophy in mice with impaired calmodulin regulation of cardiac muscle Ca release channel. J Clin Invest 2007; 117: 1344-53.
173. van Oort RJ, Respress JL, Li N, et al. Accelerated development of pressure overload-induced cardiac hypertrophy and dysfunction in an RyR2-R176Q knockin mouse model. Hypertension 55: 932-8.
174. Yamaguchi N, Xu L, Pasek DA, Evans KE, Meissner G. Molecular basis of calmodulin binding to cardiac muscle Ca(2+) release channel (ryanodine receptor). J Biol Chem 2003; 278: 23480-6.
175. Bush EW, Hood DB, Papst PJ, et al. Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J Biol Chem 2006; 281: 33487-96.
176. Ohba T, Watanabe H, Murakami M, et al. Upregulation of TRPC1 in the development of cardiac hypertrophy. J Mol Cell Cardiol 2007; 42: 498-507.
177. Onohara N, Nishida M, Inoue R, et al. TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J 2006; 25: 5305-16.
178. Kuwahara K, Wang Y, McAnally J, et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J Clin Invest 2006; 116: 3114-26.
179. Jiang LH, Gamper N, Beech DJ. Properties and therapeutic potential of TRP channels with putative roles in adversity. Curr Drug Targets 2011; 12(5): 724-36.
180. Murphy MP. Targeting lipophilic cations to mitochondria. Biochim Biophys Acta 2008; 1777: 1028-31.
181. Murphy MP, Smith RA. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev 2000; 41: 235-50.
182. James AM, Cocheme HM, Smith RA, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem 2005; 280: 21295-312.
183. Ross MF, Prime TA, Abakumova I, et al. Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells. Biochem J 2008; 411: 633-45.
184. Murphy MP, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol 2007; 47: 629-56.
185. Adlam VJ, Harrison JC, Porteous CM, et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 2005; 19: 1088-95.